KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Jazz Pharmaceuticals (JAZZ) Short-Term Debt repayments (2016 - 2017)

Jazz Pharmaceuticals has reported Short-Term Debt repayments over the past 3 years, most recently at -$350.0 million for Q4 2017.

  • Quarterly Short-Term Debt repayments fell 333.33% to -$350.0 million in Q4 2017 from the year-ago period, while the trailing twelve-month figure was -$350.0 million through Sep 2018, down 135.0% year-over-year, with the annual reading at $500.0 million for FY2020, N/A changed from the prior year.
  • Short-Term Debt repayments was -$350.0 million for Q4 2017 at Jazz Pharmaceuticals, down from $500.0 million in the prior quarter.
  • Over five years, Short-Term Debt repayments peaked at $500.0 million in Q3 2017 and troughed at -$350.0 million in Q4 2017.
  • The 3-year median for Short-Term Debt repayments is $150.0 million (2016), against an average of $121.7 million.
  • Biggest five-year swings in Short-Term Debt repayments: soared 87.5% in 2016 and later tumbled 333.33% in 2017.
  • Tracing JAZZ's Short-Term Debt repayments over 3 years: stood at $80.0 million in 2015, then soared by 87.5% to $150.0 million in 2016, then plummeted by 333.33% to -$350.0 million in 2017.
  • According to Business Quant data, Short-Term Debt repayments over the past three periods came in at -$350.0 million, $500.0 million, and $200.0 million for Q4 2017, Q3 2017, and Q2 2017 respectively.